Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?

Pediatric Infectious Disease Journal

Volumn 33, Issue SUPPL. 2, 2014, Pages

  O'Brien, Katherine L ^a   Goldblatt, David ^b   Whitney, Cynthia G ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

HEALTH CARE POLICY; HUMAN; IMMUNIZATION; MORTALITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW;

HUMANS; IMMUNIZATION SCHEDULE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; VACCINES, CONJUGATE;

EID: 84891475634     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000075     Document Type: Review

References (22)

1. O'Brien KL, Wolfson LJ, Watt JP, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. Jayakumar M. Global burden of neonatal invasive pneumococcal disease: a systematic review and meta-analysis. PhD Dissertation, Johns Hopkins Bloomberg School of Public Health; 2011.
3. Garcia CR, Johnson HL, Summers A, et al. Pneumococcal disease in older children and adults globally: results from the AGEDD project. 8th International Symposium on Pneumococci and Pneumococcal Disease; March 11-15, 2012. Igaçu Falls, Brazil.
4. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec. 2007; 82: 93-104.
5. IVAC, Johns Hopkins Bloomberg School of Public Health. Vaccine information management system (VIMS) global vaccine introduction report. December, 2012. Available at: http://www.jhsph.edu/ivac/vims.html. Accessed May 20, 2013.
6. GAVI Alliance. Countries approved for support. Geneva, Switzerland: GAVI Alliance. 2013. Available at: http://www.gavialliance.org/results/countries- approved-for-support. Available at May 20, 2013.
7. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
8. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50:1238-1246.
9. Bettinger JA, Scheifele DW, Kellner JD, et al.; Canadian Immunization Monitoring Program, Active (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine. 2010;28:2130-2136.
10. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16:816-823.
11. Durando P, Crovari P, Ansaldi F, et al.; Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine. 2009;27:3459-3462.
12. Rückinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27: 4136-4141.
13. Deceuninck G, De Wals P, Boulianne N, et al. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29:546-549.
14. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill. 2009;14:19159.
15. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8:e1001017.
16. Kenya Medical Research Institute. Pneumococcal conjugate vaccine impact study. Current disease surveillance as of April 15, 2013. Available at: http://www.kemri-wellcome.org/pcvis-current%20disease%20surveillance. Accessed May 20, 2013.
17. Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33 (Suppl 2):S152-S160.
18. Davis S, Deloria-Knoll M, O'Brien KL, for the PneumoCarr Consortium, and the PCV Dosing Landscape Project. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. [published online ahead of print May 16, 2013]. doi: 10.1016/j.vaccine.2013.05.005.
19. Russell F, Sanderson C, Temple B, et al. Global review of the distribution of pneumococcal disease by age and region: implications for vaccination schedules. 8th International Symposium on Pneumococci and Pneumococcal Disease; March 11-15, 2012. Igaçu Falls, Brazil.
20. World Health Organization. Pneumococcal Vaccines, WHO position paper -2012. Wkly Epidemiol Rec. 2012;87:129-144.
21. World Health Organization. Meeting report of PCV immunization schedules: ad hoc expert consultation. September 12, 2011. Geneva.
22. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011 -conclusions and recommendations. Wkly Epidemiol Rec. 2012;87:1-16.